Promising pre-clinical data announced for Parkinson’s drug 27 September 2021 | By Anna Begley (Drug Target Review) Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
New AI technology could shape the future of RNA therapeutics 27 September 2021 | By Anna Begley (Drug Target Review) Artificial intelligence was shown to predict the 3D shapes of RNA molecules, which could significantly advance RNA therapeutics.
Ground-breaking small molecule attenuates neuroinflammation in mice 27 September 2021 | By Anna Begley (Drug Target Review) Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
New AI method could aid in development of T cell-based cancer therapies 24 September 2021 | By Anna Begley (Drug Target Review) An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.
Sanofi acquires Translate Bio for mRNA therapeutic development 24 September 2021 | By Anna Begley (Drug Target Review) Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
Mechanism discovery provides new model for studying multiple sclerosis 23 September 2021 | By Anna Begley (Drug Target Review) The over-expression of a growth factor receptor resulted in hypomyelination, leading to diseases such as multiple sclerosis in mouse models.
Lymph node-targeted vaccine elicits COVID-19 protection in vivo 23 September 2021 | By Anna Begley (Drug Target Review) Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
Exosome-based approach reduces levels of HIV in mice 23 September 2021 | By Anna Begley (Drug Target Review) Scientists have used exosomes to deliver a novel protein that prevented HIV from replicating in the bone marrow, spleen and brain of mouse models.
Scientists uncover key that permits hepatitis C entry into cells 22 September 2021 | By Anna Begley (Drug Target Review) A new study has identified a key protein on the surface of the hepatitis C virus that interacts with a receptor found on human cells.
Nasal drugs show promise for slowing Parkinson’s disease 22 September 2021 | By Anna Begley (Drug Target Review) Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
IL13Ra2 revealed as target against breast cancer-related brain metastasis 21 September 2021 | By Anna Begley (Drug Target Review) Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.
DNA methylation could determine liver disease progression 21 September 2021 | By Anna Begley (Drug Target Review) DNA methylation at specific genomic sites was found to correlate with non-fatty liver disease and could be used to diagnose severity.
Club cell factors may reverse immune suppression in tumours 21 September 2021 | By Anna Begley (Drug Target Review) New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.
Eczema may stem from poorly regulated sex hormones, study finds 20 September 2021 | By Anna Begley (Drug Target Review) A breaking discovery has revealed the gene HSD3B1 that regulates the production of sex hormones is linked to atopic dermatitis (AD).
Controlling PTEN gene could combat paediatric rhabdomyosarcoma 20 September 2021 | By Anna Begley (Drug Target Review) The decreased expression of PTEN in mouse models was found to make rhabdomyosarcoma tumours more aggressive, highlighting new treatment approaches.
